A phase II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II)

References

• Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983; 2:355 - 7; http://dx.doi.org/10.1016/S0140-6736(83)90340-9; PMID: 6135869
   PubMed Web of Science ®Google Scholar
• Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987; 138:4402 - 7; PMID: 3108388
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, Evans A, Telford KL, Ypma E, Toneatto D, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010; 51:1127 - 37; http://dx.doi.org/10.1086/656741; PMID: 20954968
   PubMed Web of Science ®Google Scholar
• Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010; 29:e71 - 9; PMID: 20844462
   PubMed Web of Science ®Google Scholar
• Gossger N, Snape MD, Yu L-M, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, et al, European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant meningococcal serogroup B vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012; 307:573 - 82; http://dx.doi.org/10.1001/jama.2012.85; PMID: 22318278
   PubMed Web of Science ®Google Scholar
• Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A, EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013; 381:825 - 35; http://dx.doi.org/10.1016/S0140-6736(12)61961-8; PMID: 23324563
   PubMed Web of Science ®Google Scholar
• Holst J, Oster P, Arnold R, Tatley MV, Næss LM, Aaberge IS, Galloway Y, McNicholas A, O’Hallahan J, Rosenqvist E, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother 2013; 9:1241 - 53; http://dx.doi.org/10.4161/hv.24129; PMID: 23857274
   PubMed Web of Science ®Google Scholar
• Bjune G, Høiby EA, Grønnesby JK, Arnesen O, Fredriksen JH, Halstensen A, Holten E, Lindbak AK, Nøkleby H, Rosenqvist E, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338:1093 - 6; http://dx.doi.org/10.1016/0140-6736(91)91961-S; PMID: 1682541
   PubMed Web of Science ®Google Scholar
• O’Hallahan J, McNicholas A, Galloway Y, O’Leary E, Roseveare C. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. N Z Med J 2009; 122:48 - 59; PMID: 19322255
   PubMedGoogle Scholar
• Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001; 19:2688 - 91; http://dx.doi.org/10.1016/S0264-410X(00)00554-5; PMID: 11257410
   PubMed Web of Science ®Google Scholar
• Prymula R, Esposito S, Zuccotti GV, Kittel C, Toneatto D, Kohl I, Dull P. A phase 2 randomised controlled trial of a multicomponent meningococcal serogroup B vaccine (I): effects of prophylactic paracetamol on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB. Hum Vacc Immuntherapeut. Submitted
   Google Scholar
• Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009; 27:Suppl 2 B112 - 6; http://dx.doi.org/10.1016/j.vaccine.2009.04.065; PMID: 19464093
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010; 107:19490 - 5; http://dx.doi.org/10.1073/pnas.1013758107; PMID: 20962280
   PubMed Web of Science ®Google Scholar
• Lucidarme J, Newbold LS, Findlow J, Gilchrist S, Gray SJ, Carr AD, Hewitt J, Kaczmarski EB, Borrow R. Molecular targets in meningococci: efficient routine characterization and optimal outbreak investigation in conjunction with routine surveillance of the meningococcal group B vaccine candidate, fHBP. Clin Vaccine Immunol 2011; 18:194 - 202; http://dx.doi.org/10.1128/CVI.00401-10; PMID: 21123522
   PubMed Web of Science ®Google Scholar
• Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013; 13:416 - 25; http://dx.doi.org/10.1016/S1473-3099(13)70006-9; PMID: 23414709
   PubMed Web of Science ®Google Scholar
• Snape MD, Saroey P, John TM, Robinson H, Kelly S, Gossger N, Yu L-M, Wang H, Toneatto D, Dull PM, et al. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. CMAJ 2013; 185:E715 - 24; http://dx.doi.org/10.1503/cmaj.130257; PMID: 24062178
   PubMed Web of Science ®Google Scholar
• Snape MD, Philip J, John TM, Robinson H, Kelly S, Gossger N, Yu L-M, Kittel C, Toneatto D, Dull PM, et al. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. Pediatr Infect Dis J 2013; 32:1116 - 21; http://dx.doi.org/10.1097/INF.0b013e31829cfff2; PMID: 23958808
   PubMed Web of Science ®Google Scholar